Harrow, Inc. Business Combination, Contingent Consideration, Liability
Harrow, Inc. (HROW) had Business Combination, Contingent Consideration, Liability of $483.00 thousand as of 2015-03-31, per its 10-Q filed 2015-05-13.
Discontinued › Balance Sheet › Liabilities
us-gaap:BusinessCombinationContingentConsiderationLiability · last filed 2016-03-23
- 2015-03-31: Business Combination, Contingent Consideration, Liability $483.00K.
- 2014-12-31: Business Combination, Contingent Consideration, Liability $483.00K; Business Combination, Contingent Consideration, Liability as first filed $483.16K.
- 2014-09-30: Business Combination, Contingent Consideration, Liability $483.16K.
- 2014-06-30: Business Combination, Contingent Consideration, Liability $483.16K.
| Period end | Business Combination, Contingent Consideration, Liability | Business Combination, Contingent Consideration, Liability as first filed |
|---|---|---|
| 2015-03-31 | $483.00K 10-Q · filed 2015-05-13 | |
| 2014-12-31 | $483.00K 10-K · filed 2016-03-23 | $483.16K 10-K · filed 2015-03-12 |
| 2014-09-30 | $483.16K 10-Q · filed 2014-11-12 | |
| 2014-06-30 | $483.16K 10-Q · filed 2014-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |